Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 125500.0
(-2.64%)
KRW 125500.0
(-2.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 560.43 Billion KRW | 3.18% |
| 2022 | 543.16 Billion KRW | 19.15% |
| 2021 | 455.84 Billion KRW | 6.02% |
| 2020 | 429.96 Billion KRW | -0.84% |
| 2019 | 433.6 Billion KRW | 12.51% |
| 2018 | 385.37 Billion KRW | 4.71% |
| 2017 | 368.02 Billion KRW | 5.82% |
| 2016 | 347.79 Billion KRW | 34.26% |
| 2015 | 259.03 Billion KRW | 18.69% |
| 2014 | 218.24 Billion KRW | -0.95% |
| 2013 | 220.33 Billion KRW | -8.28% |
| 2012 | 240.23 Billion KRW | 0.6% |
| 2011 | 238.79 Billion KRW | 55.85% |
| 2010 | 153.21 Billion KRW | -29.4% |
| 2009 | 217.01 Billion KRW | 2.35% |
| 2008 | 212.02 Billion KRW | 13.39% |
| 2007 | 186.98 Billion KRW | 24.17% |
| 2006 | 150.59 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 138.85 Billion KRW | -7.91% |
| 2024 Q2 | 146.35 Billion KRW | 5.4% |
| 2023 FY | 560.43 Billion KRW | 3.18% |
| 2023 Q1 | 134.51 Billion KRW | -10.96% |
| 2023 Q4 | 150.77 Billion KRW | 211.27% |
| 2023 Q3 | -135.49 Billion KRW | 5.29% |
| 2023 Q2 | -143.06 Billion KRW | -206.36% |
| 2022 Q3 | 138.48 Billion KRW | 4.06% |
| 2022 Q4 | 151.06 Billion KRW | 9.08% |
| 2022 FY | 543.16 Billion KRW | 19.15% |
| 2022 Q2 | 133.08 Billion KRW | 10.42% |
| 2022 Q1 | 120.52 Billion KRW | 0.6% |
| 2021 Q3 | 111.96 Billion KRW | -5.04% |
| 2021 Q1 | 106.15 Billion KRW | -2.45% |
| 2021 Q2 | 117.91 Billion KRW | 11.07% |
| 2021 Q4 | 119.81 Billion KRW | 7.01% |
| 2021 FY | 455.84 Billion KRW | 6.02% |
| 2020 Q4 | 108.81 Billion KRW | 4.73% |
| 2020 Q1 | 106.93 Billion KRW | -6.03% |
| 2020 FY | 429.96 Billion KRW | -0.84% |
| 2020 Q3 | 103.9 Billion KRW | -5.81% |
| 2020 Q2 | 110.3 Billion KRW | 3.15% |
| 2019 FY | 433.6 Billion KRW | 12.51% |
| 2019 Q1 | 98.8 Billion KRW | -5.83% |
| 2019 Q3 | 113.49 Billion KRW | 5.57% |
| 2019 Q4 | 113.8 Billion KRW | 0.28% |
| 2019 Q2 | 107.5 Billion KRW | 8.8% |
| 2018 Q3 | 93.85 Billion KRW | -1.46% |
| 2018 FY | 385.37 Billion KRW | 4.71% |
| 2018 Q1 | 91.35 Billion KRW | -1.83% |
| 2018 Q2 | 95.24 Billion KRW | 4.26% |
| 2018 Q4 | 104.92 Billion KRW | 11.79% |
| 2017 Q1 | 87.02 Billion KRW | 1.54% |
| 2017 FY | 368.02 Billion KRW | 5.82% |
| 2017 Q4 | 93.05 Billion KRW | -2.72% |
| 2017 Q3 | 95.65 Billion KRW | 3.65% |
| 2017 Q2 | 92.29 Billion KRW | 6.05% |
| 2016 FY | 347.79 Billion KRW | 34.26% |
| 2016 Q1 | 84.09 Billion KRW | 0.35% |
| 2016 Q4 | 85.7 Billion KRW | -3.26% |
| 2016 Q3 | 88.59 Billion KRW | -0.91% |
| 2016 Q2 | 89.4 Billion KRW | 6.32% |
| 2015 FY | 259.03 Billion KRW | 18.69% |
| 2015 Q1 | 55.57 Billion KRW | -3.99% |
| 2015 Q2 | 54.68 Billion KRW | -1.61% |
| 2015 Q3 | 64.97 Billion KRW | 18.81% |
| 2015 Q4 | 83.8 Billion KRW | 28.98% |
| 2014 Q1 | 51.29 Billion KRW | -9.49% |
| 2014 FY | 218.24 Billion KRW | -0.95% |
| 2014 Q3 | 56.36 Billion KRW | 6.98% |
| 2014 Q4 | 57.88 Billion KRW | 2.69% |
| 2014 Q2 | 52.69 Billion KRW | 2.73% |
| 2013 Q2 | 52.93 Billion KRW | -7.78% |
| 2013 Q1 | 57.39 Billion KRW | 0.98% |
| 2013 FY | 220.33 Billion KRW | -8.28% |
| 2013 Q4 | 56.67 Billion KRW | 6.26% |
| 2013 Q3 | 53.33 Billion KRW | 0.76% |
| 2012 FY | 240.23 Billion KRW | 0.6% |
| 2012 Q1 | 59.09 Billion KRW | 0.0% |
| 2012 Q2 | 63.1 Billion KRW | 6.79% |
| 2012 Q3 | 59.23 Billion KRW | -6.14% |
| 2012 Q4 | 56.83 Billion KRW | -4.05% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 238.79 Billion KRW | 55.85% |
| 2011 Q3 | 57.5 Billion KRW | 0.83% |
| 2011 Q2 | 57.03 Billion KRW | 3.53% |
| 2011 Q1 | 55.08 Billion KRW | 0.0% |
| 2010 Q2 | 46.4 Billion KRW | -12.56% |
| 2010 FY | 153.21 Billion KRW | -29.4% |
| 2010 Q3 | 49.5 Billion KRW | 6.68% |
| 2010 Q1 | 53.06 Billion KRW | 6.21% |
| 2009 Q4 | 49.96 Billion KRW | -11.69% |
| 2009 FY | 217.01 Billion KRW | 2.35% |
| 2009 Q3 | 56.57 Billion KRW | -1.48% |
| 2009 Q2 | 57.42 Billion KRW | 0.0% |
| 2009 Q1 | - KRW | -100.0% |
| 2008 FY | 212.02 Billion KRW | 13.39% |
| 2008 Q3 | 51.74 Billion KRW | 4.51% |
| 2008 Q1 | - KRW | -100.0% |
| 2008 Q2 | 49.51 Billion KRW | 0.0% |
| 2008 Q4 | 55.01 Billion KRW | 6.31% |
| 2007 Q2 | 42.68 Billion KRW | 0.0% |
| 2007 FY | 186.98 Billion KRW | 24.17% |
| 2007 Q4 | 48.63 Billion KRW | 8.38% |
| 2007 Q3 | 44.87 Billion KRW | 5.12% |
| 2006 FY | 150.59 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1085.999% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -88.069% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -101.276% |
| HANDOK Inc. | 153.76 Billion KRW | -264.464% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -709.712% |
| Yuhan Corporation | 489.94 Billion KRW | -14.386% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | -82.576% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -1241.081% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 8.272% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -678.556% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -221.812% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -1299.219% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -499.061% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -388.499% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1085.999% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -1219.538% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -646.751% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -855.645% |
| JW Holdings Corporation | 301.25 Billion KRW | -86.031% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -114.761% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | -37.14% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -134.578% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -338.97% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -720.411% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -752.348% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -220.381% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -1085.999% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -124.962% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -134.578% |
| Yuhan Corporation | 489.94 Billion KRW | -14.386% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -189.384% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -706.74% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -900.197% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -134.578% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -343.404% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -374.082% |
| CKD Bio Corp. | 25.19 Billion KRW | -2124.307% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -152.448% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -239.422% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -743.801% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -338.97% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | -59.796% |
| Boryung Corporation | 285.16 Billion KRW | -96.531% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -540.185% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -221.812% |
| JW Lifescience Corporation | 20.26 Billion KRW | -2665.979% |